![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 17
2023
Käsmann, Lukas; Eze, Chukwuka; Taugner, Julian; Nieto, Alexander; Hofstetter, Kerstin; Kröninger, Sophie; Guggenberger, Julian; Kenndoff, Saskia; Flörsch, Benedikt; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus 
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403
[PDF, 1MB]
Holzgreve, Adrien ORCID: https://orcid.org/0000-0002-9566-8438; Taugner, Julian; Käsmann, Lukas; Müller, Philipp; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Winkelmann, Michael; Unterrainer, Lena M.; Nieto, Alexander E.; Bartenstein, Peter; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952; Ricke, Jens; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825; Eze, Chukwuka ORCID: https://orcid.org/0000-0003-3779-1398; Unterrainer, Marcus und Manapov, Farkhad
(2023):
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 50, Nr. 8: S. 2466-2476
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-9566-8438; Taugner, Julian; Käsmann, Lukas; Müller, Philipp; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Winkelmann, Michael; Unterrainer, Lena M.; Nieto, Alexander E.; Bartenstein, Peter; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952; Ricke, Jens; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825; Eze, Chukwuka ORCID: https://orcid.org/0000-0003-3779-1398; Unterrainer, Marcus und Manapov, Farkhad
(2023):
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 50, Nr. 8: S. 2466-2476
[PDF, 1MB]
Hofstetter, Kerstin; Taugner, Julian ORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
In: Strahlentherapie und Onkologie [Forthcoming]
[PDF, 465kB]
ORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
In: Strahlentherapie und Onkologie [Forthcoming]
[PDF, 465kB]
2022
Käsmann, Lukas; Taugner, Julian; Eze, Chukwuka; Nieto, Alexander; Pelikan, Carolyn; Flörsch, Benedikt; Kenndoff, Saskia; Hofer, Thomas P.; Nössner, Elfriede; Schulz, Christian; Unterrainer, Marcus; Tufman, Amanda; Klauschen, Frederick; Jung, Andreas; Neumann, Jens; Kumbrink, Jorg; Reinmuth, Niels; Bartenstein, Peter; Belka, Claus und Manapov, Farkhad
(2022):
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.
In: Translational Lung Cancer Research, Bd. 11, Nr. 7: S. 1503-1509
[PDF, 294kB]
Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2022):
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
In: Investigational new drugs, Bd. 40: S. 163-171
[PDF, 1MB]
Flörsch, Benedikt; Taugner, Julian; Käsmann, Lukas; Kenndoff, Saskia; Guggenberger, Julian; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2022):
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +/- immune checkpoint inhibition: a decade-long single-center historical analysis.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 3267-3276
[PDF, 1MB]
2021
Taugner, Julian; Kaesmann, Lukas; Eze, Chukwuka; Ruehle, Alexander; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
In: Investigational New Drugs, Bd. 39, Nr. 4: S. 1189-1196
Unterrainer, Marcus; Taugner, Julian; Kasmann, Lukas; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Mittlmeier, Lena M.; Bartenstein, Peter; Kunz, Wolfgang G.; Ricke, Jens; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2021):
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy +/- immune checkpoint inhibition.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 49, Nr. 4: S. 1407-1416
Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
In: Investigational New Drugs, Bd. 40, Nr. 1: S. 163-171
Taugner, Julian; Käsmann, Lukas; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.
In: Cancers, Bd. 13, Nr. 7, 1613
Stoleriu, Mircea Gabriel; Gerckens, Michael; Ströh, Katja; Kovács, Julia; Samm, Nicole; Obereisenbuchner, Florian; Hetrodt, Justin; Schmidt, Felicitas Maria; Reinmuth, Niels; Heiß-Neumann, Marion; Stacher-Priehse, Elvira; Koch, Ina; Behr, Jürgen; Ketscher, Christian; Grützner, Uwe und Hatz, Rudolf
(2021):
Prevention of COVID-19 in Thoracic Surgery Patients: Lessons Learned during the First Pandemic Wave.
In: Pneumologie, Bd. 75, Nr. 12: S. 960-970
Unterrainer, Marcus; Taugner, Julian; Käsmann, Lukas; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Mittlmeier, Lena M.; Bartenstein, Peter; Kunz, Wolfgang G.; Ricke, Jens; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2021):
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
In: European journal of nuclear medicine and molecular imaging
[PDF, 848kB]
Taugner, Julian; Käsmann, Lukas; Eze, Chukwuka; Rühle, Alexander; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2021):
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
In: Investigational new drugs, Bd. 39: S. 1189-1196
[PDF, 586kB]
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2021):
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
In: Investigational new drugs, Bd. 39: S. 1189-1196
[PDF, 586kB]
2019
Reinmuth, Niels; Bitzer, Michael; Deschler-Baier, Barbara; Fischer, Jürgen R.; Kuon, Jonas; Leipe, Jan; Rawluk, Justyna; Schulz, Christian; Heussel, Claus Peter und Schultheiss, Michael
(2019):
Nebenwirkungsmanagement in der Immunonkologie. Praktische Aspekte im Management immunvermittelter Nebenwirkungen unter immunonkologischer Therapie.
In: Deutsche Medizinische Wochenschrift, Bd. 144, Nr. 5: S. 346-353
2017
Hassel, Jessica C.; Heinzerling, Lucie; Aberle, Jens; Bähr, Oliver; Eigentler, Thomas K.; Grimm, Marc-Oliver; Grünwald, Victor; Leipe, Jan; Reinmuth, Niels; Tietze, Julia K.; Trojan, Jörg; Zimmer, Lisa und Gutzmer, Ralf
(2017):
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
In: Cancer Treatment Reviews, Bd. 57: S. 36-49
[PDF, 559kB]
2016
Eigentler, Thomas K.; Hassel, Jessica C.; Berking, Carola; Aberle, Jens; Bachmann, Oliver; Grünwald, Viktor; Kähler, Katharina C.; Loquai, Carmen; Reinmuth, Niels; Steins, Martin; Zimmer, Lisa; Sendl, Anna und Gutzmer, Ralf
(2016):
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
In: Cancer Treatment Reviews, Bd. 45: S. 7-18
2010
Dickgreber, Nicolas; Huber, Rudolf M.; Reck, Martin; Reinmuth, Niels; Schütte, Wolfgang; Serke, Monika und Wolf, Jürgen
(2010):
Aktuelle Entwicklungen und Perspektiven zielgerichteter Therapien.
In: Onkologie, Nr. 5: S. 2-11
[PDF, 653kB]